The pulmonary arterial hypertension (PAH) drugs market size is forecasted to increase by $2,080M from 2022 to 2027, at a CAGR of 6.62%, according to a study by Technavio. The growth of the market will be driven by the immunity-boosting properties of herbal medicines, low side effects, and natural healing by using herbal remedies.
By administration, the market growth will be significant in the oral segment during the forecast period. Oral administration includes tablets and suspensions, and tablets can be divided into film-coated tablets and extended-release tablets. The market segment is likely to grow during the forecast period, as these formulations do not require extensive efficacy and safety studies in animals and humans.
By action mechanism, the market growth will be significant in the prostacyclin analog segment during the forecast period. Prostacyclin analogs for PAH are drugs that lower blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs, which is a condition known as PAH. Epoprostenol, iloprost, and treprostinil are examples of prostacyclin analogs used in clinical settings. All three are used to treat PAH, a serious condition that worsens over time and is characterized by vasoconstriction and pulmonary arteriole smooth muscle cell proliferation. Thus, growing treatments related to PAH are expected to drive the growth of the prostacyclin analogs segment in the global PAH drugs market during the forecast period.
During the forecast period, the rising prevalence of PAH disease and associated hospitalizations for treatment are expected to boost the demand for related drugs. When PAH occurs, the small arteries in the lungs thicken and narrow. Blood flow through the lungs is blocked by PAHs. This increases blood pressure in the lungs and makes it difficult for the heart to pump blood through the narrowed arteries. The human heart gradually loses its ability to pump blood effectively throughout the body.